Egiroh E. Omene
Edmonton, AB, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Metabolic cell competition in the glioblastoma tumour microenvironment: glucose, glutamine, and lactate as determinants of immune exclusion and targets for pharmacological reprogramming.
Journal: Frontiers in oncology
Published: April 08, 2026
Reviewer Comment on Chahal et al. "Analysis of Bevacizumab Treatment Practices, Survival and Quality of Life Outcomes in Recurrent Glioblastoma Patients".
Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
Published: November 17, 2025
Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 07, 2025
Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.
Journal: BMC medicine
Published: April 25, 2024
Exploring psychedelic-assisted therapy in the treatment of functional seizures: A review of underlying mechanisms and associated brain networks.
Journal: Journal of psychopharmacology (Oxford, England)
Published: April 24, 2024
Switch to generic formulation of temozolomide results in statistically significant increase in grade 3 and 4 bone marrow toxicity in glioma patients in the province of Alberta.
Journal: Neuro-oncology practice
Published: March 18, 2024
Management of Bevacizumab-Induced Proteinuria Using an Angiotensin Receptor Blocker (ARB) in a Neurofibromatosis Type 2 (NF-2) Patient With Vestibular Schwannoma.
Journal: Cureus
Published: September 29, 2023
Case report: Improvement in refractory functional seizures, depression, and quality of life with ketamine-assisted therapy.
Journal: Frontiers in neuroscience
Published: March 31, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026